Latest Heptares Stories
LONDON and BOSTON, December 15, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is pleased to announce
LONDON and BOSTON, September 10, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that members
CAMBRIDGE, England, July 14, 2011 /PRNewswire/ -- Executives from O2h (Cambridge, UK) and Heptares Therapeutics (Welwyn Garden City, UK) signed an agreement to substantially increase the number of FTE chemists provided by O2h to support discovery programmes at Heptares. Dr Miles Congreve, Head of Chemistry at Heptares said, "O2h has been a valuable partner for Heptares and we are happy to further extend our synthetic chemistry team to include a full lab unit at O2h."...
ALDERLEY PARK and WELWYN GARDEN CITY, England, May 31, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). GPCRs are among the largest and most important family of proteins found in the human body, yet they become highly unstable when removed from their natural membrane-bound environments.
- To give a box on the ear to.